Federal Circuit Denies Eli Lilly En Banc Rehearing in Teva Patent Appeal

The Federal Circuit on September 30, 2026 denied Eli Lilly's petition for rehearing en banc in the Teva v. Eli Lilly dispute over Ajovy and Emgality, leaving the panel's reversal of judgment for Teva as the operative result.